000282605 001__ 282605
000282605 005__ 20251211162103.0
000282605 0247_ $$2doi$$a10.1002/dad2.70222
000282605 0247_ $$2pmid$$apmid:41367891
000282605 0247_ $$2pmc$$apmc:PMC12682591
000282605 037__ $$aDZNE-2025-01363
000282605 041__ $$aEnglish
000282605 082__ $$a610
000282605 1001_ $$0P:(DE-2719)2000026$$aTeipel, Stefan$$b0$$eFirst author
000282605 245__ $$aAssociation of cancer with neuropathological markers of Alzheimer's disease and related dementias.
000282605 260__ $$aHoboken, NJ$$bWiley$$c2025
000282605 3367_ $$2DRIVER$$aarticle
000282605 3367_ $$2DataCite$$aOutput Types/Journal article
000282605 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1765466266_17915
000282605 3367_ $$2BibTeX$$aARTICLE
000282605 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282605 3367_ $$00$$2EndNote$$aJournal Article
000282605 520__ $$aWe assessed associations of cancer diagnoses with neuropathology of Alzheimer's disease (AD) and related dementias.We retrieved 2288 cases from the National Alzheimer Coordinating Center (NACC) cohort with available information on cancer diagnoses and neuropathological scoring of Braak stages, Thal amyloid phases, neuritic plaques, TDP-43 pathology, and Lewy body pathology. We used Bayesian ordinal regression to assess associations of prevalent or incident cancer diagnoses with global cognition and postmortem neuropathological scores.We found extreme evidence (Bayes factor [BF] > 2000) that both prevalent and incident cancer diagnoses were associated with better global cognition, strong evidence (BF = 26) for an association of a prevalent cancer diagnosis with lower TDP-43 pathology, and weak evidence (BF = 3.2) for an association with lower Lewy body pathology.Our data suggest that selective survival and biological effects may contribute to the lower risk of dementia in people with a cancer diagnosis.A prevalent diagnosis of cancer was associated with a lower risk of cognitive decline in older individuals.A prevalent diagnosis of cancer was associated with a lower risk of TDP-43 pathology and Lewy body pathology in older individuals.Effects of cancer on TDP-43 pathology were maintained when controlling for degree of cognitive decline.
000282605 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000282605 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000282605 650_7 $$2Other$$aAlzheimer's disease pathology
000282605 650_7 $$2Other$$aBraak stages
000282605 650_7 $$2Other$$aTDP‐43 pathology
000282605 650_7 $$2Other$$aprotective factor
000282605 7001_ $$aAkmatov, Manas$$b1
000282605 7001_ $$0P:(DE-2719)2810763$$aMichalowsky, Bernhard$$b2$$udzne
000282605 7001_ $$aJunghanss, Christian$$b3
000282605 7001_ $$aHolstiege, Jakob$$b4
000282605 7001_ $$aBohlken, Jens$$b5
000282605 773__ $$0PERI:(DE-600)2832898-X$$a10.1002/dad2.70222$$gVol. 17, no. 4, p. e70222$$n4$$pe70222$$tAlzheimer's & dementia / Diagnosis, assessment & disease monitoring$$v17$$x2352-8729$$y2025
000282605 8564_ $$uhttps://pub.dzne.de/record/282605/files/DZNE-2025-01363.pdf$$yRestricted
000282605 8564_ $$uhttps://pub.dzne.de/record/282605/files/DZNE-2025-01363.pdf?subformat=pdfa$$xpdfa$$yRestricted
000282605 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000026$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000282605 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810763$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000282605 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000282605 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-31$$wger
000282605 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZH DEMENT-DADM : 2022$$d2024-12-31
000282605 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-31
000282605 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-31
000282605 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-08-08T17:09:24Z
000282605 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-08-08T17:09:24Z
000282605 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-08-08T17:09:24Z
000282605 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-31
000282605 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2024-12-31
000282605 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-31
000282605 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bALZH DEMENT-DADM : 2022$$d2024-12-31
000282605 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-31
000282605 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-31
000282605 9201_ $$0I:(DE-2719)1510100$$kAG Teipel$$lClinical Dementia Research (Rostock /Greifswald)$$x0
000282605 9201_ $$0I:(DE-2719)5000067$$kAG Michalowsky$$lPatient-Reported Outcomes and Health Economics Research$$x1
000282605 980__ $$ajournal
000282605 980__ $$aEDITORS
000282605 980__ $$aVDBINPRINT
000282605 980__ $$aI:(DE-2719)1510100
000282605 980__ $$aI:(DE-2719)5000067
000282605 980__ $$aUNRESTRICTED